This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.
Fergenbaum J. Harms of Prostate-Specific Antigen (PSA) screening in prostate cancer: a rapid review. Toronto: Health Quality Ontario (HQO). Rapid Review. 2015
Based on the evidence, the following conclusions can be made:
There are major harms (unnecessary risks) associated with PSA screening, including:
• harms associated with prostate biopsy
There are minor harms associated with PSA screening including:
• harms associated with PSA testing
PSA-based screening for prostate cancer results in harms related to the screening process, biopsy procedures, and, most significantly, the treatment of overdiagnosed cases. PSA-based screening of prostate cancer results in overdiagnosis and overtreatment without providing a mortality advantage, thereby exposing men to invasive treatments and potential complications. Consequently, PSA-based screening in prostate cancer results in more harm than benefit
Subject indexing assigned by CRD
Early Detection of Cancer; Humans; Male; Mass Screening /adverse effects; Prostate-Specific Antigen; Prostatic Neoplasms
Country of organisation
An English language summary is available.
Address for correspondence
Evidence Development and Standards, Health Quality Ontario, 130 Bloor Street West, 10th floor, Toronto, Ontario Canada M5S 1N5 Email: EDSinfo@hqontario.ca
Date abstract record published